Characterization of the clinical evolution of nasopharyngeal carcinoma in a Portuguese population;Caracterización de la evolución clínica del carcinoma de la nasofaringe en una población Portuguesa

Acta Otorrinolaringologica Espanola

Volumn 58, Issue 5, 2007, Pages 191-197

  Breda, Eduardo ^a   Catarino, Raquel ^a   Azevedo, Isabel ^a   Fernandes, Tomé ^a   Da Costa, Carlos Barreira ^a   Medeiros, Rui ^a,b  

^a PORTUGUESE ONCOLOGY INSTITUTE   (Portugal)

^b UNIVERSITY OF PORTO   (Portugal)

Author keywords

Clinical evolution; Histological subtypes; Nasopharyngeal carcinoma; Staging systems; Survival; Treatment

Indexed keywords

BLEOMYCIN; CISPLATIN; DACARBAZINE; DOXORUBICIN; FLUOROURACIL; METHOTREXATE; VINBLASTINE;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CLASSIFICATION; CANCER MORTALITY; CANCER PATIENT; CANCER SURVIVAL; CAUSE OF DEATH; DISEASE COURSE; FEMALE; FOLLOW UP; HISTOLOGY; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NASOPHARYNX CARCINOMA; PORTUGAL; PREDICTION; SQUAMOUS CELL CARCINOMA; SURVIVAL RATE;

EID: 34547877654     PISSN: 00016519     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0001-6519(07)74911-7     Document Type: Article

References (24)

1. Jackson C. Primary carcinoma of the nasopharynx: a table of cases. JAMA. 1901;37:371-7.
2. a ed. p. 314.
3. Mendenhall WM. Nasopharynx. En: Millio RR, Cassisi NJ editores. Management of head and neck cancer, a multidisciplinary approach. 2.a ed. Philadelphia: JB Lippincott; 1994. p. 599-626.
4. Ferlay J, et al (2001) GLOBOCAN 2000; Cancer Incidence, Mortality and Prevalence Worlwide. IARC Cancer Base n.o 5, IARC base Lyon.
5. Parkin DM, Whelan SL, Ferlay J, Raymond L, Young J. Cancer incidence in Five Continents. Vol. 7. Lyon: IARC Scientific Publications; 1997.
6. Vikram B. Carcinoma of the nasopharynx. Clin Oncol. 1986;5:475-83.
7. a ed. Geneva: WHO; 1991. p. 32-3.
8. Lo KW, To KF, Huang DP. Focus on nasopharyngeal carcinoma [revisión]. Cancer Cell. 2004;5:423-8.
9. Busson P, Keryer C, Ooka T, Corbex M. EBV-associated nasopharyngeal carcinomas: from epidemiology to virus-targeting strategies [revisión]. Trends Microbiol. 2004;12:356-60.
10. Niedobitek G. Epstein-Barr virus infection in the pathogenesis of nasopharyngeal carcinoma [revisión]. Mol Pathol. 2000;53:248-54.
11. Niedobitek G. The Epstein-Barr virus: a group 1 carcinogen? [revisión]. Virchows Arch. 1999;435:79-86.
12. Pagano JS. Epstein-Barr virus: the first human tumor virus and its role in cancer [revisión]. Proc Assoc Am Physicians. 1999;111:573-80.
13. Langendijk JA, Leemans CR, Buter J, Berkhof J, Slotman BJ. The additional value of chemotherapy to radiotherapy in locally advanced nasopharyngeal carcinoma: a meta-analysis of the published literature. J Clin Oncol. 2004;22:4604-12.
14. Rivera S, Keryer C, Busson P, Maingon P. [Nasopharyngeal carcinomas: from biology to clinic] [revisión]. Cancer Radiother. 2005;9:55-68.
15. Palazzi M, Guzzo M, Tomatis S, Cerrotta A, Potepan P, Quattrone P, et al. Improved outcome of nasopharyngeal carcinoma treated with conventional radiotherapy. Int J Radiat Oncol Biol Phys. 2004;60:1451-8.
16. Ma BB, Chan AT. Recent perspectives in the role of chemotherapy in the management of advanced nasopharyngeal carcinoma [revisión]. Cancer. 2005;103:22-31.
17. Chua DT, Ma J, Sham JS, Mai HQ, Choy DT, Hong MH, et al. Long-term survival after cisplatin-based induction chemotherapy and radiotherapy for nasopharyngeal carcinoma: a pooled data analysis of two phase III trials. J Clin Oncol. 2005;23:1118-24.
18. Disponible en: http://www-dep.iarc.fr/globocan/database.htm
19. Lee AW, Poon YF, Foo W, Law SC, Cheung FK, Chan DK, et al. Retrospective analysis of 5037 patients with nasopharyngeal carcinoma treated during 1976-1985: overall survival and patterns of failure. Int J Radiat Oncol Biol Phys. 1992;23:261-70.
20. Spano JP, Busson P, Atlan D, Bourhis J, Pignon JP et al. Nasopharyngeal Carcinoma: an update. Eur J Cancer. 2003;39:2121-35.
21. 9th International Nasopharynx Cancer Study Group (INCSG) Preliminary results of a randomized trial comparing neoadjuvant quemoterapy plus radiotherapy versus radiotherapy alone in stage IV (N2-N3, M0) undifferentiated nasopharyngeal carcinoma: a positive effect on progression-free survival. VUMCA I trial. Int J Radiat Oncol Biol Phys. 1996;35:463-9.
22. Neel HB, Taylor WF. Clinical presentation and diagnosis of nasopharyngeal carcinoma: current status. En: Prasad U, Ablashi DV, Levine PH, et al, editores. Nasopharyngeal carcinoma: current concepts. 1983. p. 10.
23. Dickson RI. Nasopharyngeal carcinoma: an evaluation of 209 patients. Laryngoscope. 1981;91:333-53.
24. Chua DT, Sham JS, Wei WI, Ho WK, Au GK. The predictive value of the 1997 American Joint Committee on cancer stage classification in determining failure patterns in nasopharyngeal carcinoma. Cancer. 2001;92:2845-55.